BACKGROUND: : Tumor angiogenesis has been associated with a poor prognosis in patients with metastatic melanoma (MM). Microtubule stabilizers and cyclooxygenase 2 (COX-2) inhibitors, alone and in combination, have produced inhibitory effects on endothelial cells and tumor angiogenesis. Angiogenesis, which is the growth of new blood vessels, is necessary for tumor growth and progression. Thus, the authors tested the safety and efficacy of a low dose of paclitaxel and celecoxib in patients with MM. METHODS: : Patients received paclitaxel 10 mg/m(2) for 96 hours weekly as a continuous intravenous infusion and oral celecoxib 400 mg twice daily. Systemic tumor response was assessed at 6-week intervals. Tumor measurements at the end of Cycle 1 were used as the baseline for assessment of tumor progression. Patients with unacceptable toxicity or disease progression after Cycle 2 relative to the end of Cycle 1 were taken off study. RESULTS: : Twenty patients were enrolled. Twelve of 20 patients (60%) had received > or =2 previous systemic therapies. Three patients did not receive treatment because of rapid disease progression. Treatment-related grade 3/4 toxicities were limited to catheter-related complications. One patient achieved a partial response, and 3 of 20 patients (15%) had stable disease for >6 months. The median time to progression was 57 days (95% confidence interval, 43-151 days), and the median overall survival was 212 days (95% confidence interval, 147-811 days). CONCLUSIONS: : Low-dose, continuous intravenous infusion paclitaxel and oral celecoxib produced disease stabilization in a significant proportion of heavily pretreated patients with MM. These findings support a role for metronomic therapy in patients with this disease. Cancer 2010. (c) 2010 American Cancer Society.
BACKGROUND: : Tumor angiogenesis has been associated with a poor prognosis in patients with metastatic melanoma (MM). Microtubule stabilizers and cyclooxygenase 2 (COX-2) inhibitors, alone and in combination, have produced inhibitory effects on endothelial cells and tumor angiogenesis. Angiogenesis, which is the growth of new blood vessels, is necessary for tumor growth and progression. Thus, the authors tested the safety and efficacy of a low dose of paclitaxel and celecoxib in patients with MM. METHODS: : Patients received paclitaxel 10 mg/m(2) for 96 hours weekly as a continuous intravenous infusion and oral celecoxib 400 mg twice daily. Systemic tumor response was assessed at 6-week intervals. Tumor measurements at the end of Cycle 1 were used as the baseline for assessment of tumor progression. Patients with unacceptable toxicity or disease progression after Cycle 2 relative to the end of Cycle 1 were taken off study. RESULTS: : Twenty patients were enrolled. Twelve of 20 patients (60%) had received > or =2 previous systemic therapies. Three patients did not receive treatment because of rapid disease progression. Treatment-related grade 3/4 toxicities were limited to catheter-related complications. One patient achieved a partial response, and 3 of 20 patients (15%) had stable disease for >6 months. The median time to progression was 57 days (95% confidence interval, 43-151 days), and the median overall survival was 212 days (95% confidence interval, 147-811 days). CONCLUSIONS: : Low-dose, continuous intravenous infusion paclitaxel and oral celecoxib produced disease stabilization in a significant proportion of heavily pretreated patients with MM. These findings support a role for metronomic therapy in patients with this disease. Cancer 2010. (c) 2010 American Cancer Society.
Authors: Yuval Shaked; Francesco Bertolini; Shan Man; Michael S Rogers; Dave Cervi; Thomas Foutz; Kimberley Rawn; Daniel Voskas; Daniel J Dumont; Yaacov Ben-David; Jack Lawler; Jack Henkin; Jim Huber; Daniel J Hicklin; Robert J D'Amato; Robert S Kerbel Journal: Cancer Cell Date: 2005-01 Impact factor: 31.743
Authors: C M Balch; A C Buzaid; S J Soong; M B Atkins; N Cascinelli; D G Coit; I D Fleming; J E Gershenwald; A Houghton; J M Kirkwood; K M McMasters; M F Mihm; D L Morton; D S Reintgen; M I Ross; A Sober; J A Thompson; J F Thompson Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: M E Christine Lutsiak; Roshanak T Semnani; Roberto De Pascalis; Syed V S Kashmiri; Jeffrey Schlom; Helen Sabzevari Journal: Blood Date: 2004-12-09 Impact factor: 22.113
Authors: Jaime R Merchan; Deepa R Jayaram; Jeffrey G Supko; Xiaoying He; Glenn J Bubley; Vikas P Sukhatme Journal: Int J Cancer Date: 2005-01-20 Impact factor: 7.396
Authors: Domingo G Perez; Vera J Suman; Tom R Fitch; Thomas Amatruda; Roscoe F Morton; Shamim Z Jilani; Costas L Constantinou; James R Egner; Lisa A Kottschade; Svetomir N Markovic Journal: Cancer Date: 2009-01-01 Impact factor: 6.860
Authors: S Anthony Kahn; Christine M Mullin; Louis-Philippe de Lorimier; Kristine E Burgess; Rebecca E Risbon; Rogers M Fred; Kenneth Drobatz; Craig A Clifford Journal: Can Vet J Date: 2013-03 Impact factor: 1.008
Authors: Michael Lidsky; Gamil Antoun; Paul Speicher; Bartley Adams; Ryan Turley; Christi Augustine; Douglas Tyler; Francis Ali-Osman Journal: J Biol Chem Date: 2014-07-25 Impact factor: 5.157
Authors: Ewelina Kluza; Marieke Heisen; Sophie Schmid; Daisy W J van der Schaft; Raymond M Schiffelers; Gert Storm; Bart M ter Haar Romeny; Gustav J Strijkers; Klaas Nicolay Journal: Angiogenesis Date: 2011-01-12 Impact factor: 9.596
Authors: Stephan W Reinhold; Albrecht Reichle; Sonja Leiminger; Tobias Bergler; Ute Hoffmann; Bernd Krüger; Bernhard Banas; Bernhard K Krämer Journal: BMC Res Notes Date: 2011-01-05